CALLAN JMB INC. (CJMB) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Callan JMB Inc (CJMB) 3-Minute Overview > **💡 One-Sentence Summary** > > Callan JMB is a tiny U.S. logistics company trying to reinvent itself as a specialized cold-chain and emergency-response infrastructure player for high-value healthcare and GLP‑1 drugs, but it’s currently very unprofitable and still in “story stock” territory. > **📍 Basic Profile** > > Market Cap **$8.4 million** · Logistics & Transportation (healthcare / cold-chain focus) · NASDAQ · Price **$1.81** --- > **⚡ 3 Things You Should Know** > > 1. ⚠️ Deep in the red: Net margin around **-113%** and ROE roughly **-133%** scream “early-stage / turnaround” rather than a stable business—right now every dollar of revenue is losing more than a dollar. > > 2. 🎯 Big strategic pivot: Management is shifting hard into **cold-chain infrastructure for GLP‑1 drugs and life sciences** plus federal/emergency stockpile work, which is a large, growing niche if they can actually win and execute contracts. > > 3. 👀 Insider buying, tiny float: The founder and insiders have been **actively buying shares**, and with a market cap of only ~$8m and the stock trading near its 52‑week low after falling from ~$7.8, this is a **high-risk, high-volatility microcap bet**, not a “sleep well at night” holding. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-------------------|------------------|---------| > | Profitability | Weak👎 | Net margin about **-112.7%**, operating margin **-98%** despite decent gross margin | > | Growth Rate | [Data unavailable] | No revenue/earnings history provided; story driven more by news than numbers | > | Financial Health | Healthy💚 | Current ratio **3.6**, quick ratio **2.5**, debt-to-equity **0** (no leverage) | > | Valuation | [Story-driven] | No PE (loss-making); PS ~**1.34x** for a very speculative turnaround | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Cold-chain logistics, storage, and specialized fulfillment services sold to healthcare companies, pharma, and emergency/federal agencies, earning revenue from storage, handling, monitoring, and deployment services. **Revenue Breakdown:** (Exact segment numbers aren’t given, but based on descriptions:) | Business | Share | Trend | Comment | |----------------------------------------------|-------|-------|---------| | Cold-chain logistics & life sciences fulfillment | [Data unavailable] | ↑ | Strategic pivot toward GLP‑1 and higher-value healthcare logistics; focus area going forward | | Federal/emergency management & stockpile-related services | [Data unavailable] | ↑ | Leveraging “Strategic National Stockpile” relationships and federal contracts per news | | Legacy/general logistics | [Data unavailable] | ↓/→ | Likely less central to the new story; not highlighted in recent news | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |---------------|-----------:|-----------------|----------------| | Gross Margin | 36.7% | Above-average | The core services have okay unit economics; the problem is overhead/scale, not pricing power alone. | | Net Margin | -112.7% | Bottom tier | Heavy losses—either too small scale, high fixed costs, or significant upfront investment. | | ROE | -133.4% | Very weak | Equity base is being heavily eroded; this is classic early-stage / distressed profile. | In other words: the *service* isn't inherently low-margin, but the company is far from break-even. --- ### 📈 How’s the Growth? **Growth Assessment:** **Unknown / story-driven** (no explicit growth numbers in the data) | Metric | Latest | vs Last Year | Trend | |----------------|---------------|------------------|---------| | Revenue Growth | [Unavailable] | [Unavailable] | [N/A] | | Profit Growth | [Unavailable] | [Unavailable] | [N/A] | **Growth Quality:** What we *can* infer from the news: - They just announced a **“major strategic pivot”** toward cold-chain for the GLP‑1 market and retrofitting a Texas cGMP facility. - They also signed an **Attune partnership** for **$50–75m total revenue** over time (aggregate, not annual), covering manufacturing oversight, federal deployment, and commercialization. For a company with only an ~$8m market cap, that $50–75m figure, if realized over a reasonable time frame, is huge relative to its size. But: - Timing, margins, and cash collection are unknown. - Execution risk (build, qualify, operate, and staff facilities) is significant. So growth is **potentially large in percentage terms**, but mainly **forward-looking and unproven**. --- ### 💰 Financial Health Check **One Sentence:** Think of CJMB as someone with no mortgage and decent cash on hand, but whose salary is negative—living off savings and needing a much better job soon. | Metric | Value | Safe Zone | Assessment | |-----------------|--------:|---------------|------------| | Debt Ratio | 0 | <60% safe | ✅Safe – essentially no leverage, which buys time. | | Current Ratio | 3.60 | >1.5 healthy | ✅Comfortable – can cover short-term obligations easily. | | Quick Ratio | 2.47 | >1.0 | ✅Liquid – not dependent on moving inventory to pay bills. | | Cash Flow | [Not given] | >0 | ⚠️Unknown – margins suggest likely operating cash burn. | So: - **Balance sheet looks light and liquid**: no meaningful debt, good short-term liquidity. - The **income statement is the pain point**, not the balance sheet—for now. - If losses persist, they’ll likely need **dilution or new funding** down the line. --- ### 🏷️ Is It Expensive Now? **Price Position (52-week range):** - 52-Week Low: **$1.08** - 52-Week High: **$7.76** - Current: **$1.81** (was +5.2% on the last trading day) Position in range: - Range width ≈ 7.76 - 1.08 = 6.68 - Current offset ≈ 1.81 - 1.08 = 0.73 - Position ≈ 0.73 / 6.68 ≈ **11%** (very close to the low) | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------:|----------:|------------:| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ●(11%) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |---------------|-----------------|-----------------|------------| | vs Own History | PE: N/A (loss) | 5-year avg N/A | Purely narrative-driven; no earnings anchor. | | vs Peers | PS ~1.34x | Logistics usually <1–2x | Not ridiculous on sales alone, but risk-adjusted this is still speculative. | **What the Current Valuation is Betting On:** At a ~$8m market cap and PS ~1.3x, the market is: - Not paying a huge multiple on current/near-term revenue, but - Effectively **pricing in some probability** that: - The **GLP‑1 cold-chain strategy and Attune deal** actually generate tens of millions of revenue. - Losses narrow substantially without blowing up the balance sheet. - NASDAQ listing is maintained and they avoid a death-spiral of dilution. If those things don’t materialize, even a “cheap-looking” PS multiple won’t protect you. --- ### 📰 Any Recent News? | Date (approx.) | Event | Impact | |----------------|-------|--------| | 2026-01-12 | Announces **pivot to cold-chain infrastructure** for GLP‑1 market; retrofitting Texas cGMP facility. | **Positive / High-risk** – Opens a big new market but requires capex, regulatory and execution muscle. | | 2026-01-15 | Signs **Attune agreement** for manufacturing oversight, federal deployment, and commercialization; total revenue potential **$50–75m**. | **Positive** – If delivered, could be transformational vs <$10m market cap; details (timing/margins) matter a lot. | | Late 2025 | Founder **Wayne Williams** and other insiders buy additional shares (multiple small open market purchases). | **Mildly positive** – Signals management confidence, but size vs their total holdings and personal wealth is unknown. | | Jan 2026 | Mentioned among “Top Midday Gainers” / “Most Active Stocks”. | **Neutral** – Indicates trading interest/volatility, not fundamentals. | --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data (The raw time series isn’t given; here’s what we know and can infer.) **Profitability Trends (directional only):** | Metric | This Year (TTM) | Last Year | Year Before | 3-Year Trend | |-------------|------------------|-----------|-------------|--------------| | Gross Margin | 36.7% | [N/A] | [N/A] | [Unknown] | | Net Margin | -112.7% | [N/A] | [N/A] | [Unknown, but clearly loss-making now] | | ROE | -133.4% | [N/A] | [N/A] | [Unknown; likely negative for some time] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |---------------|-----------|-----------|-------------|--------------| | Revenue Growth | [N/A] | [N/A] | [N/A] | [Unknown] | | Profit Growth | [N/A] | [N/A] | [N/A] | [Unknown] | | EPS Growth | [N/A] | [N/A] | [N/A] | [Unknown] | Key takeaway: Without full historicals, you have to treat CJMB as a **“special situation” microcap**, not a standard compounder with clean trend lines. --- ### II. Earnings Track Record **Last 4 Quarters vs Expectations:** Earnings history and consensus estimates: **not available** (no data in the feed). | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [MRQ] | [N/A] | [N/A] | [N/A] | | ... | | | | **Earnings Trend Interpretation:** - No analyst coverage in the dataset and no visible earnings “beat/miss” pattern. - For such a small cap, **market moves are more tied to press releases, contracts, and liquidity** than to quarterly EPS. --- ### III. What the Market Thinks **Analyst Ratings:** (From provided data) | Rating | Count | Percentage | |-----------------|-------|------------| | Strong Buy/Buy | 0 | 0% | | Hold | 0 | 0% | | Sell | 0 | 0% | No published analyst recommendations here—this is typical for a tiny microcap. **Target Price:** No data → effectively, **no institutional “anchor”** for valuation. **Insider Activity (last few months):** All listed insider codes are “P” (purchase): - Founder **Wayne Williams**: multiple buys in Dec 2025, including small incremental adds on successive days (e.g., +4,926 shares; +10,810; +5,000; etc.). - Other insiders (e.g., **Gerald Dial**, **Liberty Smith Duke**) also bought modest amounts. > Insider buying usually signals either **genuine confidence** or management trying to show skin in the game. The absolute dollar amounts aren’t huge, but directionally it’s a positive signal compared to insiders dumping stock. --- ### IV. Key Risk Alerts 1. **Sustainability of Operations (Profitability Risk):** - Current margins (net around -113%) imply **ongoing cash burn**. - If the Attune deal and cold-chain pivot don’t quickly turn into profitable, cash-generating contracts, they may need **dilutive equity raises** or other financing. → That could crush existing shareholders even if the business survives. 2. **Execution & Concentration Risk (Strategy Risk):** - The new story leans heavily on **cold-chain GLP‑1 infrastructure and federal/emergency-related contracts**. - Winning, implementing, and renewing such contracts requires regulatory compliance, operational reliability, and political/budget stability. → If a few key deals are delayed, cancelled, or underprice risk, revenues could fall far short of that touted $50–75m pipeline. 3. **Microcap / Liquidity Risk (Market Risk):** - With a **market cap of ~$8m**, daily dollar volume and liquidity are likely thin and volatile (news already put it in “Most Active / Top Gainers” lists). - Spreads can be wide; exits in a panic can be hard, and NASDAQ listing compliance (e.g., minimum bid price) can become an issue if the price stays low. → Expect big swings on news and **potential delisting/dilution scenarios** if the stock stays depressed. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Callan JMB is a tiny U.S. logistics company trying to reposition itself as a specialized cold-chain and emergency-response infrastructure platform for high-value healthcare, especially GLP‑1 drugs. > **Key strength:** It has a clean, low-debt balance sheet, growing ties to federal/emergency and life sciences work (including a $50–75m Attune agreement), and visible insider buying that suggests management believes in the pivot. > **Key risk:** The business is currently deeply unprofitable, highly dependent on a few big strategic bets actually landing and scaling, and trades as an illiquid, story-driven microcap where dilution and volatility are very real possibilities. > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis of its cold-chain competitive edge and contract durability. > • Want to check for hidden landmines? → Try【Muddy Mode】to dig into listing risk, potential dilution, and regulatory/contract risks. > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】to model different revenue scenarios for the GLP‑1 and Attune pipelines vs today’s ~$8m market cap.